Evidence map›Paper›PMID 40347359›Full record

ReviewDrugs2025

The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety.

Livio Pagano, Romano Danesi, Edoardo Benedetti, Riccardo Morgagni, Luigina Romani, Adriano Venditti

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Hematopoietic Aging and Leukemia: Mechanistic and Therapeutic Insights.International journal of molecular sciences · 2026
    Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Livio PaganoDepartment of Laboratory and Hematological Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0001-8287-928X
Romano DanesiDepartment of Oncology and Hemato-Oncology, University of Milan "La Statale", 7, Via Festa del Perdono, 20122, Milan, Italy. romano.danesi@unimi.it.ORCID http://orcid.org/0000-0002-4414-8934
Edoardo BenedettiHematology Operative Unit (UO), Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.ORCID http://orcid.org/0000-0001-5295-2087
Riccardo MorgagniDepartment of Cardiology and Interventional Cardiology, University Tor Vergata, Rome, Italy.ORCID http://orcid.org/0009-0004-9672-2733
Luigina RomaniDepartment of Medicine and Surgery, University of Perugia, P.le Lucio Severi 1, Perugia, Italy.ORCID http://orcid.org/0000-0002-1356-525X
Adriano VendittiHematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.ORCID http://orcid.org/0000-0002-0245-0553

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CPX-351 (also known as VYXEOS

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCytarabineDaunorubicinLeukemia, Myeloid, AcuteAnimalsHumansLiposomesAntineoplastic AgentsCPX-351CytarabineDaunorubicinLiposomes

Identifiers

PMID40347359
PMCPMC12185649

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.